Therapeutic applications of gut microbes in cardiometabolic diseases: current state and perspectives
Yuan, Lin,Li, Ying,Chen, Moutong,Xue, Liang,Gu, Qihui,Zhang, Jumei,Zhao, Hui,Xie, Xinqiang,Wu, Qingping
DOI: https://doi.org/10.1007/s00253-024-13007-7
IF: 5
2024-01-21
Applied Microbiology and Biotechnology
Abstract:Cardiometabolic disease (CMD) encompasses a range of diseases such as hypertension, atherosclerosis, heart failure, obesity, and type 2 diabetes. Recent findings about CMD's interaction with gut microbiota have broadened our understanding of how diet and nutrition drive microbes to influence CMD. However, the translation of basic research into the clinic has not been smooth, and dietary nutrition and probiotic supplementation have yet to show significant evidence of the therapeutic benefits of CMD. In addition, the published reviews do not suggest the core microbiota or metabolite classes that influence CMD, and systematically elucidate the causal relationship between host disease phenotypes-microbiome. The aim of this review is to highlight the complex interaction of the gut microbiota and their metabolites with CMD progression and to further centralize and conceptualize the mechanisms of action between microbial and host disease phenotypes. We also discuss the potential of targeting modulations of gut microbes and metabolites as new targets for prevention and treatment of CMD, including the use of emerging technologies such as fecal microbiota transplantation and nanomedicine.
biotechnology & applied microbiology